HighTower Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.48M | Sell |
11,198
-1,073
| -9% | -$142K | ﹤0.01% | 1912 |
|
|
2025
Q4 | $1.74M | Buy |
12,271
+2,822
| +30% | +$409K | ﹤0.01% | 1746 |
|
|
2025
Q3 | $1.33M | Sell |
9,449
-214
| -2% | -$29K | ﹤0.01% | 1904 |
|
|
2025
Q2 | $1.21M | Sell |
9,663
-21
| -0.2% | -$2.41K | ﹤0.01% | 1882 |
|
|
2025
Q1 | $1.07M | Sell |
9,684
-916
| -9% | -$116K | ﹤0.01% | 1923 |
|
|
2024
Q4 | $1.45M | Buy |
10,600
+1,013
| +11% | +$125K | ﹤0.01% | 1720 |
|
|
2024
Q3 | $1.1M | Sell |
9,587
-19,785
| -67% | -$2.71M | ﹤0.01% | 1876 |
|
|
2024
Q2 | $4.07M | Buy |
29,372
+13,434
| +84% | +$1.84M | 0.01% | 1092 |
|
|
2024
Q1 | $2.21M | Buy |
15,938
+556
| +4% | +$75.9K | ﹤0.01% | 1379 |
|
|
2023
Q4 | $2.03M | Buy |
15,382
+8,149
| +113% | +$938K | ﹤0.01% | 1420 |
|
|
2023
Q3 | $821K | Buy |
7,233
+625
| +9% | +$65.8K | ﹤0.01% | 1905 |
|
|
2023
Q2 | $626K | Sell |
6,608
-1,297
| -16% | -$127K | ﹤0.01% | 2044 |
|
|
2023
Q1 | $811K | Sell |
7,905
-381
| -5% | -$39.6K | ﹤0.01% | 1805 |
|
|
2022
Q4 | $997K | Buy |
8,286
+2,550
| +44% | +$299K | ﹤0.01% | 1675 |
|
|
2022
Q3 | $607K | Sell |
5,736
-57
| -1% | -$5.78K | ﹤0.01% | 1902 |
|
|
2022
Q2 | $566K | Buy |
5,793
+48
| +0.8% | +$4.43K | ﹤0.01% | 1968 |
|
|
2022
Q1 | $544K | Buy |
5,745
+1,883
| +49% | +$160K | ﹤0.01% | 2117 |
|
|
2021
Q4 | $332K | Sell |
3,862
-2,142
| -36% | -$197K | ﹤0.01% | 2417 |
|
|
2021
Q3 | $581K | Sell |
6,004
-26,344
| -81% | -$2.49M | ﹤0.01% | 1973 |
|
|
2021
Q2 | $3.15M | Buy |
32,348
+26,406
| +444% | +$2.53M | 0.01% | 983 |
|
|
2021
Q1 | $574K | Buy |
5,942
+224
| +4% | +$23.5K | ﹤0.01% | 1894 |
|
|
2020
Q4 | $551K | Sell |
5,718
-2,465
| -30% | -$238K | ﹤0.01% | 1592 |
|
|
2020
Q3 | $789K | Buy |
8,183
+3,631
| +80% | +$420K | ﹤0.01% | 1344 |
|
|
2020
Q2 | $555K | Sell |
4,552
-131
| -3% | -$14.5K | ﹤0.01% | 1405 |
|
|
2020
Q1 | $405K | Sell |
4,683
-267
| -5% | -$26.1K | ﹤0.01% | 1421 |
|
|
2019
Q4 | $532K | Buy |
4,950
+296
| +6% | +$31K | ﹤0.01% | 1421 |
|
|
2019
Q3 | $419K | Sell |
4,654
-34
| -0.7% | -$3.18K | ﹤0.01% | 1607 |
|
|
2019
Q2 | $396K | Buy |
4,688
+226
| +5% | +$18.6K | ﹤0.01% | 1636 |
|
|
2019
Q1 | $393K | Buy |
4,462
+356
| +9% | +$29.8K | ﹤0.01% | 1584 |
|
|
2018
Q4 | $293K | Sell |
4,106
-22
| -0.5% | -$2.11K | ﹤0.01% | 1616 |
|
|
2018
Q3 | $508K | Buy |
4,128
+22
| +0.5% | +$2.5K | ﹤0.01% | 1458 |
|
|
2018
Q2 | $404K | Sell |
4,106
-7
| -0.2% | -$627 | ﹤0.01% | 1538 |
|
|
2018
Q1 | $342K | Buy |
4,113
+1,307
| +47% | +$110K | ﹤0.01% | 1613 |
|
|
2017
Q4 | $218K | Buy |
+2,806
| New | +$191K | ﹤0.01% | 1866 |
|
Other funds holding NBIX
VPM
VCM
HighTower Advisors's NBIX Position: Q1 2026 in Review
HighTower Advisors reduced its Neurocrine Biosciences (NBIX) stake by 8.7% in Q1 2026, selling an estimated $142K and leaving 11,198 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1912.
HighTower Advisors first reported a position in NBIX in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.07M in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- HighTower Advisors held 11,198 shares of Neurocrine Biosciences worth $1.48M as of Q1 2026.
- HighTower Advisors sold 1,073 Neurocrine Biosciences shares in Q1 2026, an estimated $142K.
- Neurocrine Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1912 holding.
- HighTower Advisors first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 34 quarters since.
- HighTower Advisors's Neurocrine Biosciences position peaked at $4.07M in Q2 2024.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.